Orthocell Limited Overview
Orthocell is a Perth-based regenerative medicine company that has completed its transition from research to commercial operations. Its business is built on SMRT™, a proprietary process that preserves the native structure of collagen without crosslinking or chemical modification. Two collagen medical devices on that platform generate most of its revenue. Remplir™ is a nerve wrap for peripheral nerve repair, and Striate+™ is a dental guided bone regeneration membrane licensed globally to BioHorizons, part of the Henry Schein group. Orthocell owns its intellectual property and manufactures every device at an ISO 13485-certified facility in Perth, which lets it keep the manufacturing margin while choosing a different route to market in each country. The investment case rests on converting the April 2025 FDA 510(k) clearance for Remplir into repeat US surgical use in a market the company sizes at US$1.6bn. Supporting legs are UK/EU approval, a new nerve-sparing prostate surgery indication and a tendon pipeline (SmrtWrap™). The balance sheet is well funded (A$44M) but the company is still loss-making, with an FY26 net loss of A$13.9M.
Company's own description (FY2026 Annual Report, paraphrased)
In its FY2026 Annual Report, Orthocell describes itself as a company that develops, manufactures and commercialises regenerative medicine products for repairing nerve, bone, tendon and cartilage tissue. Its products are designed to work with the body's natural healing, to simplify complex surgery, to shorten operating time and to produce consistent results. It names Remplir™ (collagen nerve wrap) and Striate+™ (resorbable collagen membrane for guided bone and tissue regeneration) as its principal commercial products. It also markets OrthoACI™, an autologous cartilage cell therapy, in Australia, and is developing SmrtWrap™, a collagen tendon repair device. All devices are made at its ISO 13485-certified Perth facility from Australian-sourced collagen raw material and supplied internationally through specialist distributors, a global partner (BioHorizons) and an in-house US commercial team.
Business model
The FY2026 Annual Report describes an integrated model resting on three capabilities.
-
Proprietary technology. The SMRT™ collagen processing platform, developed over more than a decade, is fully owned by Orthocell and carries no royalties on device sales.
-
Owned Australian manufacturing. Every Remplir and Striate+ unit sold worldwide is made in Perth. The devices have a three-year shelf life, so production can be centralised and shipped to North America, Europe, Asia-Pacific and Latin America. CEO Paul Anderson summarises the rationale as owning the manufacturing so that the company also owns the manufacturing margin.
-
Market-specific routes to market:
-
Striate+: an exclusive 25-year global licence and supply arrangement with BioHorizons Implant Systems. Orthocell is the contract manufacturer and BioHorizons sells under its own commercial infrastructure. About 60,000 units were manufactured for BioHorizons in FY26.
-
Remplir in Australia, New Zealand and Singapore: exclusive distribution by Device Technologies Group.
-
Remplir in other international markets: specialist distributors, including MontsMed (Hong Kong), two distributors in Canada, LEDA Orthopaedics (UK, pre-launch) and MediTime (Thailand).
-
Remplir in the United States: a hybrid model. An internal team covering sales, medical education, marketing and medical affairs supports 18 specialist distributors across more than 20 states, about 50% population coverage at 30 June 2026.
-
Revenue model and mix
Orthocell earns revenue from four sources:
Product sales (point in time): Remplir sold to distributors and hospitals, Striate+ sold to BioHorizons, and OrthoACI cell therapy procedures in Australia.
- Licence and contract revenue (deferred, recognised over time): BioHorizons paid an upfront US$16M (A$23.1M) on signing in July 2022. It sits as a contract liability that is released to revenue over time. The balance was A$16.07M at 30 June 2025 (A$2.30M current, A$13.77M non-current) and A$13.78M at 30 June 2026 (A$2.31M current, A$11.46M non-current), which implies about A$2.3M of non-cash revenue recognised each year. That run-rate is the analyst's inference from the movement in the balance sheet line.
Finance income: A$1.82M in FY26, interest on cash and term deposits. It sits outside statutory revenue but is included in management's headline "revenue".
Grant income: principally the Australian R&D Tax Incentive refund, A$3.0M in FY26, booked below gross profit.
The company has no subscription or service revenue. A full statutory split of FY26 revenue by product (Remplir, Striate+ manufacturing, licence amortisation, OrthoACI) is not publicly disclosed in the documents reviewed. The disclosed data points are:
-
Australian Remplir revenue exceeded A$1.5M in the June 2026 quarter alone, from more than 1,000 procedures.
-
US Remplir revenue was A$0.33M in the June 2026 quarter and A$0.92M cumulative since launch.
-
International Remplir sales were more than 9% of quarterly revenue in Q4 FY26.
Value chain position, customers and end-markets
Orthocell is vertically integrated from raw collagen processing through to the finished sterile device. It does not run its own sales operations outside the US.
Direct customers:
-
distributors (Device Technologies, MontsMed, LEDA, MediTime, US specialist distributors);
-
a strategic licensee (BioHorizons);
-
hospitals in the US, which buy after Value Analysis Committee (VAC) approval.
End users:
-
microsurgically trained hand, plastic and orthopaedic surgeons (peripheral nerve);
-
urologists (nerve-sparing radical prostatectomy);
-
dental implant surgeons and periodontists (Striate+);
-
orthopaedic surgeons (OrthoACI and the tendon programmes).
End-markets: peripheral nerve repair, which the company sizes at US$1.6bn in the US and about US$750M in the UK/EU; dental guided bone regeneration membranes (about US$735M globally for Striate+'s addressable segments); tendon repair; and cartilage repair.
Independent characterisation
Orthocell is best understood as a sub-scale but commercially validated single-platform biomaterials manufacturer. Its value depends overwhelmingly on Remplir's US adoption curve.
The Striate+ business is effectively a contract manufacturing annuity plus licence amortisation. It brings external validation from a Henry Schein subsidiary and production scale, but Orthocell has limited control over its growth.
The Australian Remplir franchise proves the product commercially. Its scale (370 surgeons and 239 hospitals since launch, more than 1,000 procedures a quarter) is the strongest evidence in the dossier.
The US is still in the market-access phase. In FY26, 70 hospitals and 76 surgeons generated only about A$0.9M of cumulative revenue, and management itself frames the next year as a test of repeat use. The company is not yet a growth-at-scale medtech. It is funded, de-risked on regulatory grounds, and now exposed mainly to commercial execution risk.
Strategy
Stated strategy (FY2026 Annual Report)
The FY2026 Annual Report sets out five pillars:
-
"Win in the Americas": US commercialisation of Remplir.
-
Continue growth in ANZ and Asia.
-
Expand the global footprint: Canada, UK/EU and humanitarian programmes.
-
Advance the product platform: prostate indication, SmrtWrap and the PearlBone option.
-
Build capability for future growth: manufacturing, automation, ERP and digital marketing.
The Chair describes the aim as building a global regenerative medicine company on proprietary Australian technology, high-quality manufacturing and products that meet real clinical needs. The US nerve repair market is the single largest focus.
FY27 priorities (CEO letter, FY2026 Annual Report)
-
Deepen Remplir adoption and repeat use in the US, through targeted sales, education and marketing support for distributors.
-
Grow established markets.
-
Prepare selectively for further international launches, with UK/EU first.
-
Advance product opportunities that broaden the portfolio.
The Q4 FY26 presentation adds a target of about 80% US distributor coverage, up from about 50%.
Strategic initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| US Remplir launch | April 2025 onward | FDA clearance; 18 distributors; internal team; DoD/VA access | Ongoing; adoption phase |
| A$17M placement | December 2024 / January 2025 | At A$0.60 to fund the US launch | Completed |
| A$30M placement | October 2025 | About 23.1M shares at A$1.30 | Completed |
| UK/EU market entry | December 2025 submission; March 2026 distributor | LEDA Orthopaedics appointed for the UK | Approval expected by end CY2026 |
| Nerve-sparing prostatectomy | From mid-2025 | More than 250 procedures, 39 surgeons, five Australian states | Data expected 2H CY2026; US market opportunity flagged |
| Marine Biomedical / PearlBone | MoU October 2025; closed January 2026 | A$1.005M for a 12.17% stake and first right of refusal on distribution | Completed |
| Stage 1 manufacturing expansion | Approved FY26 | About A$5.0–5.5M; about four times installed capacity; more automation | Construction 2H CY2026 |
| ERP and digital systems | Live April 2026 | Finance, inventory, CRM | Completed |
| SmrtWrap US regulatory programme | FY26 | Tendon repair 510(k) pathway | In progress |
| Humanitarian programme | FY26 | Remplir supplied to support war victims in Ukraine | Ongoing |
| Digital marketing | FY26 | Global Remplir awareness programme | Launched |
Medium-term targets and guidance
Orthocell does not give quantitative revenue or earnings guidance. Its qualitative guidance has three parts:
-
Revenue growth is expected to continue and accelerate in FY27 as market access turns into routine use.
-
Current funds are said to be sufficient to reach anticipated breakeven without more capital (Q4 FY26 presentation).
-
Long-standing market-share aspiration: a 20% share target for Striate+ and Remplir in their addressable markets (Stockhead, 2024).
No ESG targets and no cost-reduction programmes with numerical targets are disclosed.
Products & Services
Remplir™ (peripheral nerve repair)
| Attribute | Detail |
|---|---|
| Description | Collagen nerve wrap made with the SMRT™ process. It provides a compression-free environment around repaired nerves and mimics the epineurium (the outer layer of a nerve) |
| Indications / uses | One device for connecting severed nerves (coaptation), protecting damaged nerves, or capping amputated nerve ends. Emerging use in nerve-sparing radical prostatectomy |
| Company-stated benefits | Exceptional handling; fewer sutures needed; supports return of the nerve towards its pre-injury state |
| Target customer | Microsurgically trained hand, plastic, orthopaedic and peripheral nerve surgeons; urologists |
| Regulatory status | Cleared or approved in Australia (TGA, March 2022), New Zealand, Singapore, the US (FDA 510(k), 3 April 2025), Canada, Hong Kong and Thailand. UK/EU application lodged December 2025, with approval expected by the end of calendar 2026 |
| Commercial status | Australia: more than 1,000 procedures in Q4 FY26, 370 surgeons and 239 hospitals since launch. US: 18 distributors, 70 purchasing hospitals, 76 surgeons, 119 units in Q4 FY26, 44 VAC approvals giving access to 151 hospitals, and DoD/VA network access (221 centres). First sales in Hong Kong (December 2025), Canada (April 2026) and Thailand (September 2026) |
| US go-to-market focus | Crush, compression and short-gap nerve injuries, where management believes Remplir meets a clear need without competing head-on with established products |
| Clinical evidence | US 510(k) nerve repair study met all endpoints (December 2024). The company announced an 81% success rate on 8 September 2025. Prostate data (more than 250 procedures by 39 surgeons) is expected in 2H CY2026 |
| Pricing | Not publicly disclosed. In 2022 the company applied for Australian Prostheses List reimbursement under a code paying A$1,380 per unit. The company cites an average of about 1.7 units per procedure (StockWireX summary of the Q3 FY26 presentation) |
| Launch year | Australia 2022; US June 2025 |
Striate+™ (dental guided bone and tissue regeneration)
| Attribute | Detail |
|---|---|
| Description | Pure, acellular, resorbable collagen membrane that is not crosslinked. It keeps gingival tissue out of the bone defect so that bone can form |
| Indications | Guided bone regeneration and guided tissue regeneration in dental implant and periodontal procedures |
| Target customer | Dental implant surgeons and periodontists, reached through BioHorizons |
| Regulatory status | US (FDA 510(k), January 2021), Australia, New Zealand, Singapore, UK, Europe (CE), Canada, Brazil (ANVISA, April 2025). Registered or approved in FY26 in Hong Kong, Colombia, Ecuador and Chile |
| Commercial | Exclusive 25-year global licence to BioHorizons (Henry Schein). Orthocell manufactures in Perth; about 60,000 units in FY26 |
| Pricing | Not publicly disclosed (supply price to BioHorizons confidential) |
| Company claims | Described as the first product approved for dental guided bone regeneration on its platform; a 98% success rate is cited in company materials reported by Stockhead |
OrthoACI™ (autologous chondrocyte implantation)
| Attribute | Detail |
|---|---|
| Description | Cell therapy that uses the patient's own chondrocytes (cartilage cells) to regenerate damaged articular cartilage, most often in the knee and ankle. Each procedure is customised |
| Regulatory | Available in Australia; made under TGA manufacturing licence MI-19052008-LI-002420-11, which covers tissue processing and release of autologous tenocytes and chondrocytes |
| Target customer | Orthopaedic surgeons and patients with symptomatic cartilage defects |
| Pricing / revenue | — |
Ortho-ATI™ (autologous tenocyte implantation)
A cell therapy that injects the patient's own tendon-derived cells under ultrasound guidance to treat chronic tendinopathy, approved by the TGA before the 2014 IPO. Company boilerplate says Orthocell is advancing its tendon cell therapy in the US through technology transfer and FDA engagement to confirm the US pathway and prepare for partnering discussions. Current revenue contribution is not publicly disclosed.
SmrtGraft™ / SmrtWrap™ (tendon repair, pipeline)
A collagen device that extends the SMRT™ platform into tendon repair. SmrtGraft is available in Australia under the Special Access Scheme or in a clinical trial. In the June 2024 quarter the company described it as a planned third revenue-generating product. A US regulatory programme for SmrtWrap™ began in FY26. The December 2025 quarterly report referred to an FDA 510(k) submission expected by March 2026; whether it was lodged is not confirmed in the documents reviewed.
PearlBone™ (option, through Marine Biomedical)
A marine-derived bone repair product being developed by Marine Biomedical, in which Orthocell holds 12.17%. Orthocell has a first right of refusal over global distribution and sees it as a potential complement to Striate+. It is not yet approved.
CelGro™ (platform brand, historical)
CelGro was the original name of the collagen scaffold platform from which Striate+ and Remplir were derived. Current materials refer instead to the "SMRT™ collagen platform".
Financial Narrative
Data quality. FY2025 and FY2026 figures come from the audited FY2026 Annual Report, which includes FY2025 comparatives. Treat the earlier figures as indicative. Blank cells mean not publicly disclosed or not derivable.
Income statement
Notes:
-
The operating result is the loss before tax minus finance income. It still includes grant income, currency effects and share of associate loss.
-
EBITDA is not publicly disclosed, and the depreciation and amortisation charge was not in the extracted statements.
-
The Motley Fool (3 September 2026) reported the FY26 net loss as A$13.6M, up 59%. That matches total comprehensive loss (A$13.58M). The statutory loss after tax is A$13.91M, up 62%.
-
FY2022–FY2024 EPS is from InvestSMART (cents per share converted to dollars).
Margins and growth
The FY2022–FY2024 net margins are analyst-computed from the aggregator figures. InvestSMART's own net margins are -147.3% for FY2023 and -135.1% for FY2024, based on its own revenue definitions.
Revenue CAGR, FY2022–FY2026:
-
Statutory: A$1.5M to A$11.41M is roughly 66% a year.
-
Headline: A$1.62M to A$13.2M is roughly 69% a year.
Both bases are low, so the compounding rate exaggerates commercial scale.
Balance sheet
Notes:
-
FY2026 short-term debt is the A$0.58M insurance premium finance plus A$0.40M current leases. Long-term debt is A$0.57M of non-current leases. There is no bank debt.
-
Goodwill is nil throughout. FY2026 intangibles are A$0.77M.
-
FY2022–FY2023 total debt is from InvestSMART (about A$0.56M).
-
FY2024 equity is the 1 July 2024 opening balance in the FY2026 report's statement of changes in equity. FY2022–FY2023 equity is from InvestSMART.
Structural observation. About two-thirds of total liabilities (A$13.78M of A$20.40M in FY26) are non-cash deferred revenue from BioHorizons. These are performance obligations, not borrowings, so financial leverage is effectively zero.
Cash flow
Notes:
-
FY2023 operating cash flow was boosted by the A$23.1M BioHorizons upfront payment.
-
FY2022–FY2024 capex uses total investing cash flow as a proxy (aggregator).
-
FY2024 R&D refund received is per the June 2024 quarterly report.
Ratios
Notes:
-
ROE for FY2025 uses average equity of FY2024 (A$4.53M) and FY2025.
-
ROIC is not meaningful: the company is loss-making and invested capital is negative once deferred revenue is netted.
-
Net debt to EBITDA and interest coverage are not meaningful, because the company has net cash, negative EBITDA and minimal interest paid (A$13.7k in FY26).
-
A full cash conversion cycle cannot be computed reliably because payables include operating expenses. Receivable and inventory days are analyst-computed.
Commentary on trends, inflections and drivers
Revenue quality is improving. The gross margin step-up from 45.7% to 58.7% in FY26, with gross profit up 86% against revenue up 45%, reflects three things: more high-value Remplir sales in the mix, a fixed licence amortisation of about A$2.3M against a rising revenue base, and manufacturing scale from producing about 60,000 Striate+ units. That leverage should continue as Remplir volumes build. The Stage 1 expansion targets about four times current installed capacity, which will temporarily lift fixed costs before it improves unit economics.
Operating expenses are growing faster than revenue. Selling and marketing rose 62% to A$8.51M, which is the US commercial build-out. Administration nearly doubled-plus (+126%) to A$9.52M as management, the ERP system and corporate infrastructure expanded. Share-based payments rose 146% to A$3.02M. R&D fell 33% to A$4.02M after the US 510(k) study ended. FY26 is therefore the first year in which commercial investment, not R&D, drives the loss. The FY26 pre-tax loss of A$13.9M is 62% wider than FY25.
The headline revenue measure flatters underlying sales. Including interest income (A$1.82M) and non-cash licence amortisation (about A$2.3M) means roughly A$4.1M of the A$13.2M headline in FY26 is not recurring cash product revenue. Customer receipts of A$7.96M (including GST) are the better cash proxy, though they were up 55% year on year.
Cash burn has risen, but liquidity is strong. Operating cash outflow was A$12.74M and free cash flow about -A$14.0M in FY26. Against A$43.95M of cash and deposits, that is about three years of runway at the FY26 rate. Management quotes 4.6 years using a more recent quarterly burn rate; the Q3 FY26 quarter was described as broadly cash breakeven, helped by the A$3.0M R&D refund. Management says it does not need further funding to reach breakeven, but no breakeven date has been given.
Inflection to monitor. The investment thesis needs revenue to grow faster than selling, general and administrative costs from FY27. With the FY27 STI scorecard weighted more heavily towards US revenue, management incentives are aligned with that.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Statutory revenue (AUD Mn) | 1.5 | 4.2 | 5.3 | 7.85 | 11.41 |
Cost of goods sold (AUD Mn) | — | — | — | 4.26 | 4.71 |
Gross profit (AUD Mn) | — | — | — | 3.58 | 6.69 |
Finance income (AUD Mn) | — | — | — | 1.30 | 1.82 |
Grant income incl. R&D tax incentive (AUD Mn) | — | — | — | 3.25 | 3.00 |
R&D expense (AUD Mn) | — | — | — | 6.01 | 4.02 |
Selling and marketing expense (AUD Mn) | — | — | — | 5.26 | 8.51 |
Administration and general expense (AUD Mn) | — | — | — | 4.21 | 9.52 |
Share-based payments expense (AUD Mn) | — | — | — | 1.23 | 3.02 |
Operating result excl. finance income, analyst-derived (AUD Mn) | — | — | — | -9.87 | -15.73 |
Pre-tax loss (AUD Mn) | -9.11 | -6.25 | -7.18 | -8.57 | -13.91 |
Net loss after tax (AUD Mn) | -9.11 | -6.25 | -7.18 | -8.57 | -13.91 |
Basic EPS (AUD) | -0.047 | -0.032 | -0.035 | -0.038 | -0.053 |
Diluted EPS (AUD) | -0.047 | -0.032 | -0.035 | -0.038 | -0.053 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin on statutory revenue (%) | — | — | — | 45.7 | 58.7 |
Net margin on statutory revenue (%) | -607 | -149 | -135 | -109 | -122 |
Statutory revenue growth YoY (%) | — | 180 | 26 | 48 | 45 |
Headline revenue growth YoY (%) | — | 219 | 31 | 35 | 45 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 11.02 | 24.82 | 20.61 | 28.62 | 9.45 |
Term deposits over 3 months (AUD Mn) | — | — | — | 0 | 34.50 |
Total cash and term deposits (AUD Mn) | 11.02 | 24.82 | 20.61 | 28.62 | 43.95 |
Trade and other receivables (AUD Mn) | — | — | — | 1.85 | 2.85 |
Inventories (AUD Mn) | — | — | — | 1.20 | 1.69 |
Total current assets (AUD Mn) | — | — | — | 31.83 | 49.80 |
Property, plant and equipment (AUD Mn) | — | — | — | 1.80 | 2.47 |
Intangible assets, no goodwill (AUD Mn) | — | — | — | 1.07 | 0.77 |
Investment in associate (AUD Mn) | — | — | — | 0 | 0.91 |
Total assets (AUD Mn) | — | — | — | 35.24 | 54.81 |
Total current liabilities (AUD Mn) | — | — | — | 6.40 | 8.34 |
Lease liabilities, total (AUD Mn) | — | — | — | 0.58 | 0.97 |
Insurance premium finance, short-term debt (AUD Mn) | — | — | — | 0 | 0.58 |
Total debt incl. leases (AUD Mn) | 0.56 | 0.56 | — | 0.58 | 1.55 |
Net debt, negative = net cash (AUD Mn) | — | — | — | -28.04 | -42.40 |
Contract liabilities, BioHorizons (AUD Mn) | — | — | — | 16.07 | 13.78 |
Total liabilities (AUD Mn) | — | — | — | 20.67 | 20.40 |
Total equity (AUD Mn) | 9.9 | 6.1 | 4.53 | 14.57 | 34.41 |
Working capital (AUD Mn) | — | — | — | 25.43 | 41.46 |
NTA per share (AUD) | — | — | — | 0.0555 | 0.1235 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers incl. GST (AUD Mn) | — | — | — | 5.15 | 7.96 |
R&D tax incentive received (AUD Mn) | — | — | 3.05 | 3.19 | 3.00 |
Operating cash flow (AUD Mn) | -6.26 | 14.59 | -6.51 | -8.68 | -12.74 |
Capex, PP&E plus intangibles (AUD Mn) | -0.54 | -0.63 | -0.94 | -0.36 | -1.27 |
Free cash flow, OCF minus capex (AUD Mn) | -6.80 | 13.96 | -7.45 | -9.04 | -14.01 |
Equity raised, net of costs, incl. options (AUD Mn) | — | — | — | 17.26 | 30.21 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2025 | FY2026 |
|---|---|---|
ROE on average equity (%) | -89 | -57 |
ROA on average assets (%) | — | -31 |
Current ratio (x) | 4.97 | 5.97 |
Debt to equity incl. leases (x) | 0.04 | 0.05 |
Asset turnover, revenue to average assets (x) | — | 0.25 |
Receivable days (days) | 86 | 91 |
Inventory days on COGS (days) | 103 | 131 |
Revenue by Region and Operating Metrics (units)
| Metric | FY2024 | FY2026 |
|---|---|---|
US Remplir revenue (AUD Mn) | 0 | 0.92 |
Australia Remplir revenue, Q4 only (AUD Mn) | — | 1.5 |
US Remplir units, Q4 only (units) | 0 | 119 |
Region Overview
| Region | Products | Status | Growth assessment |
|---|---|---|---|
Australia / NZ | Remplir (Device Technologies), Striate+ (BioHorizons), OrthoACI | Mature; the largest Remplir market | Steady growth; more than 1,000 procedures a quarter; prostate indication adds a new channel |
United States | Remplir (hybrid), Striate+ (BioHorizons) | Year 1 of Remplir; Striate+ since November 2022 | Fastest growing from a small base: Q4 FY26 Remplir A$0.33M, up 10% on the prior quarter. Slower than access metrics suggest because hospital VAC approval and surgeon adoption take time |
Canada | Remplir (2 distributors), Striate+ | First Remplir sale April 2026 | Early |
Asia (Singapore, Hong Kong, Thailand) | Remplir, Striate+ | Singapore since December 2024; Hong Kong December 2025; Thailand September 2026 | Early; Singapore surgical cases growing |
Europe / UK | Striate+ (BioHorizons Camlog, DACH from March 2025); Remplir pending | UK/EU Remplir decision expected by end CY2026 | Material optionality from FY27 |
Latin America | Striate+ (Brazil, Colombia, Ecuador, Chile) | BioHorizons preparing launches | Early |
Valuation Snapshot
| Metric | Value | Source / Date |
|---|---|---|
IPO price | 0.40 | August 2014 |
Recent price | 0.74 to 0.775 | InvestSMART, 25 September 2026; MarketScreener, 29 September 2026 |
52-week range | 0.67 to 1.60 | MarketScreener / Investing.com |
3-year range | 0.32 to 1.79 | MarketScreener |
1-year change | About -35% to -43% | Motley Fool, 3 September 2026; Investing.com, August 2026 |
Year to date 2026 | About -28% | MarketScreener, 29 September 2026 |
3-year change | About +100% (from a 30-day VWAP of about A$0.38 in August 2024 to about A$0.77) | FY24 company presentation; analyst calculation |
5-year change | About 12.5% a year on average (5-year average annual growth to April 2026) | Pearler |
Placement reference prices | A$0.60 (January 2025); A$1.30 (October 2025) | Company filings |
Share Price
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Share price near year end (AUD) | 0.38 | 1.24 | 0.85 |
Valuation Multiples
| Multiple | Orthocell | Note |
|---|---|---|
EV (AUD) | About 158M | Market cap minus A$43.95M cash, plus A$1.55M debt and leases |
EV / Sales (statutory FY26) | About 13.9x | — |
EV / Sales (headline FY26) | About 12.0x | — |
EV / Sales (consensus FY27) | 9.2x | MarketScreener |
P/B | About 5.9x | Equity A$34.41M |
P/E 2027 / 2028 (consensus) | -14.9x / -37.3x | MarketScreener; implies losses narrowing |
Analyst Ratings & Targets
| Broker | Rating | Target (AUD) | Date / Source |
|---|---|---|---|
Bell Potter | Speculative Buy | 1.24 (raised from 1.15) | FNArena; Motley Fool, 3 September 2026 |
Canaccord Genuity | Speculative Buy | 1.26 (after Q3 FY26); 1.33 earlier in 2026 | FNArena; MarketScreener |
Euroz Hartleys | Covers stock (Q1 FY26 in line with expectations) | — | MarketScreener, October 2025 |
Consensus (Investing.com) | 2 Buy | Average 1.225 (range 1.19 to 1.26) | August 2026 |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
There is no numerical guidance. Management expects revenue growth to continue and accelerate through FY27, driven by repeat US use, expanded US coverage (aiming for about 80%), UK/EU approval by end CY2026, Thailand and Canada ramping up, and Striate+ expansion. It says current funds are enough to reach breakeven without new capital. The Stage 1 manufacturing expansion (A$5.0–5.5M) begins construction in 2H CY2026.
Consensus
Consensus data is thin, with two or three brokers. MarketScreener's EV/Sales multiples imply consensus revenue rising sharply into FY28 (9.2x FY27 against 4.69x FY28 on a similar EV, which implies close to a doubling between FY27 and FY28). Consensus EPS points to losses continuing through FY28 but narrowing. FNArena shows a single-broker FY27 EPS forecast of about -4.1 cents.
Bull case
-
The US flywheel is set up. VAC approvals give access to 151 hospitals, while only 70 have purchased and 76 surgeons are active. Australian benchmarks of more than 1,000 procedures a quarter, from a population about one-thirteenth the size of the US, show what penetration could look like. Even modest US use (for example 1,000 units a quarter) would multiply the current US run-rate of about A$0.33M a quarter.
-
Operating leverage is visible. A gross margin of 58.7% and rising, a four-fold capacity expansion and no royalties mean incremental revenue flows through at high margins once the selling and administration base is built.
-
Several catalysts. UK/EU approval, prostate data, the SmrtWrap 510(k) and broker targets of about A$1.19–1.26 (about 60–70% upside) give a re-rating path, against an EV of about A$158M that is covered almost 30% by cash.
Bear case
-
Conversion risk is real. Q3 FY26 group revenue was flat quarter on quarter and US Remplir grew only 10% in Q4. With 76 surgeons generating about A$0.33M a quarter (about A$4,300 per surgeon), repeat use has not been demonstrated.
-
The loss is structurally rising. Operating expenses grew far faster than gross profit (+A$6.5M of selling and administration against +A$3.1M of gross profit in FY26). Free cash flow of -A$14.0M implies only about three years of runway on actual FY26 burn, below management's 4.6-year figure, so a further raise is plausible if US uptake stays slow.
-
Headline growth overstates underlying growth. About 30% of headline FY26 "revenue" is interest income and non-cash licence amortisation. Axogen, an entrenched competitor about 20 times larger with favourable 2026 CMS coding, limits Orthocell's ability to set prices and move beyond niche indications.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / Monitorable |
|---|---|
| Mid to late October 2026 | Q1 FY27 Quarterly Report and Appendix 4C (September 2026 quarter): US Remplir revenue, units, active surgeons, repeat-ordering data |
| Q4 CY2026 | 2026 AGM, including the vote on appointing Deloitte as auditor and the remuneration report |
| By end CY2026 | UK/EU regulatory decision on Remplir |
| 2H CY2026 | Initial prostatectomy clinical performance data |
| 2H CY2026 | Stage 1 manufacturing construction starts |
| January 2027 | Q2 FY27 quarterly report |
| February 2027 | 1H FY27 results: operating expense trajectory, cash burn |
| FY27 | Progress towards 80% US distributor coverage; outcome of the SmrtWrap 510(k) |
| Ongoing | Monthly US unit run-rate; adoption in DoD/VA centres; Thailand and Canada ramp; BioHorizons Latin America orders |
Analyst verdict
Orthocell has done what many small-cap Australian medtechs never manage. It has built an owned, royalty-free manufacturing platform, won FDA clearance for its flagship product, signed a blue-chip licensee and raised enough capital to fund a multi-year commercial launch. The Australian Remplir franchise, with more than 1,000 procedures a quarter, is real proof that surgeons will adopt the product when it is properly supported. The FY26 gross margin step-up to 58.7% shows that the manufacturing model gets more profitable as volumes grow.
The market's reaction to the company's "record" quarters is instructive, though. The shares fell about 15–18% on the Q4 FY26 update and are down about 35–43% over the year, despite 45% revenue growth. Investors have recognised what the headline numbers obscure. Roughly A$4M of the A$13.2M headline is interest income and licence amortisation. US Remplir revenue is still below A$0.4M a quarter after a full year in market. Operating costs are growing about twice as fast as gross profit.
The equity therefore behaves like a call option on US repeat use. With an EV of about A$158M, Orthocell trades at about 12–14 times trailing sales, a large premium to profitable, faster-scaling nerve repair peers on absolute economics. The cash position limits downside in the near term.
Our assessment is Neutral to Speculative Positive. The thesis improves materially if the next two quarterly reports show US Remplir revenue rising above about A$0.6M a quarter on clear repeat-use metrics, together with UK/EU approval. It deteriorates if US revenue plateaus, because the FY26 cash burn implies a further equity raise before breakeven. The key metric is not total revenue, hospital count or distributor coverage, but US revenue per active surgeon over time.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Qualifications | Independent |
|---|---|---|---|---|---|
John Van Der Wielen | Non-Executive Chair | 1 June 2023 | More than 30 years in wealth management, private banking and insurance; former CEO of HBF Health; Chair of the Perth Mint and the Future Health Research and Innovation Fund; senior adviser to Appian Capital Advisory and Bridgewest Group | MBA (UWA), FAICD | Yes |
Paul Anderson | CEO & Managing Director | Co-founder (2006) | More than 25 years in medical devices and cell therapy; former MD of Verigen Australia (acquired by Vericel); aggregator-listed age 60 | BHSc | No |
Dr Ravi I. Thadhani | NED; Lead Independent Director | 8 March 2023 | EVP, Chief Physician Executive and Dean of the Medical Faculty, Cedars-Sinai; more than 300 publications; former FDA advisory committee member | MD, MPH | Yes |
Prof. Fiona Wood AM | NED | 1 November 2023 | Plastic and reconstructive surgeon; co-inventor of "spray-on skin"; Australian of the Year 2005 | MBBS, FRACS | Yes |
Michael McNulty | NED; Chair of Audit & Risk and of Remuneration & Nomination | 1 September 2025 | Former Deloitte partner (22 years); director of Gold Corporation (Perth Mint); NED of Southern Cross Electrical Engineering (ASX:SXE) | BCom, FCA, GAICD | Yes |
Kim Beazley AC | Former NED | 15 January 2024 to 25 July 2025 | Former Deputy Prime Minister, Ambassador to the US and Governor of WA | MPhil, MA | Yes (resigned) |
Peter Webse | Company Secretary | — | Director of Governance Corporate Pty Ltd | BBus, FGIA, FCG | — |
Executive Leadership Team
| Name | Title | Tenure / Start | Prior roles |
|---|---|---|---|
Paul Anderson | CEO & MD | Since 2006 | Verigen Australia MD |
Prof. Ming Hao Zheng AM | Chief Scientific Officer | Since 2006 (co-founder, inventor of the core technology) | Director of Research in Orthopaedic Surgery, UWA; PhD and MD (UWA); FRCPath |
Jim Piper | Chief Financial Officer | From 1 August 2025 | Pilbara Minerals, Fortescue Metals Group, Accenture CFO advisory; Chartered Accountant; 2004 Olympian swimmer |
Alex McHenry | Chief Operating Officer | KMP in FY26 (earlier start date not disclosed) | Arthur Andersen; corporate finance across biotech and resources |
Tony Macintyre | Chief Technical Operations Officer | — | More than 25 years in manufacturing and laboratory operations; former director of CareDx Pty Ltd |
Adam Wood | Chief Commercial Officer | — | LifeHealthcare; EBOS MedTech |
John Walker; Phillip Edmondson | US commercial executives (appointed January 2025) | January 2025 | Axogen nerve repair sales leadership; current titles and status not confirmed in the FY26 report |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary & Fees | STI Cash | Super | Leave & Other | SBP STI | SBP LTI | Retention Rights | Total FY26 | Total FY25 |
|---|---|---|---|---|---|---|---|---|---|
Paul Anderson (CEO) | 475,859 | 120,395 | 30,000 | 52,970 | 30,916 | 77,595 | 364,500 | 1,152,235 | 859,888 |
Alex McHenry (COO) | 329,821 | 63,922 | 26,394 | 26,863 | 19,562 | 74,280 | 79,448 | 620,290 | — |
Jim Piper (CFO, part year) | 297,923 | 57,986 | 29,000 | 33,186 | 19,349 | 73,481 | 81,832 | 592,757 | — |
Non-Executive Director | Fees | Super | Share-based payments | Total FY26 | Total FY25 | — | — | — | — |
John Van Der Wielen | 168,453 | 10,714 | 29,167 | 208,334 | 150,000 | — | — | — | — |
Dr Ravi Thadhani | 129,335 | 0 | 12,554 | 141,889 | 115,285 | — | — | — | — |
Prof. Fiona Wood | 89,583 | 0 | 8,750 | 98,333 | 75,000 | — | — | — | — |
Michael McNulty (from 1 September 2025) | 74,404 | 8,929 | 313,750 | 397,083 | — | — | — | — | — |
Kim Beazley (to 25 July 2025) | 6,250 | 0 | 0 | 6,250 | 75,000 | — | — | — | — |
Major Shareholders
| Holder | Shares | Approx. % | Source / Note |
|---|---|---|---|
Paul Anderson (CEO) | 7,378,900 | 2.7% | FY2026 Annual Report; plus 2.57M equity incentives |
Unnamed holder (MarketScreener list) | 7,073,975 | 2.6% | Name not disclosed in source |
Unnamed holder | 5,996,241 | 2.2% | Name not disclosed in source |
Unnamed holder | 4,785,445 | 1.8% | Name not disclosed in source |
Wyllie Group Pty Ltd | 4,614,992 | 1.7% | MarketScreener |
Unnamed holder | 4,300,000 | 1.6% | Name not disclosed in source |
University of Western Australia | 2,360,973 | 0.9% | MarketScreener |
Unnamed holder | 2,048,677 | 0.8% | Name not disclosed in source |
Unnamed holder | 1,784,911 | 0.7% | Name not disclosed in source |
Rubino Group Pty Ltd | 1,583,334 | 0.6% | MarketScreener |
Competitive Landscape
Competitors by Segment
| Area | Competitor | Products | Notes |
|---|---|---|---|
Peripheral nerve (US leader) | Axogen Inc. (NASDAQ: AXGN) | Avance® nerve graft (FDA BLA approved in 2025); Axoguard Nerve Connector, Protector and Cap | FY2025 revenue US$225.2M (+20.2%); gross margin 74.3%; 2026 guidance of at least 18% growth (Axogen FY2025 10-K / press release) |
Peripheral nerve | Integra LifeSciences (NASDAQ: IART) | NeuraGen® nerve guide, NeuraWrap™ protector | — |
Peripheral nerve | Collagen Matrix, Inc. | NeuroMatrix™, NeuroFlex™ collagen conduits and wraps | Private |
Peripheral nerve | Polyganics | Neurolac® synthetic conduit | Private (Netherlands) |
Peripheral nerve | Baxter (formerly Synovis) | GEM Neurotube® | Diversified |
Peripheral nerve | Tissium | — | Private (France) |
Dental membranes | Geistlich Pharma | Bio-Gide® collagen membrane (category leader) | Private (Switzerland) |
Dental membranes | Straumann Group | Jason® membrane and others | Listed (SIX) |
Dental membranes | ZimVie / Zimmer Biomet Dental | BioMend® collagen membranes | Listed |
Dental membranes | Dentsply Sirona | Regenerative membranes | Listed |
Tendon | Smith+Nephew | REGENETEN™ bioinductive implant | Listed |
Cartilage | Vericel Corp. | MACI® (autologous cultured chondrocytes) | Listed (NASDAQ: VCEL) |
Peer Comparison FY2026
| Metric | Orthocell (FY26, A$) | Axogen (FY25, US$) |
|---|---|---|
Revenue | A$11.4M statutory / A$13.2M headline | US$225.2M |
Revenue growth | +45% | +20.2% |
Gross margin | 58.7% | 74.3% |
Net margin | -122% | -7.0% (net loss US$15.7M) |
R&D intensity | 35% of revenue | — |
Recent Developments
There have been no layoffs, guidance revisions, litigation or regulatory enforcement actions in the period.



